Hyperoside attenuates diabetic nephropathy by activating the Nrf2/SLC7A11/GPX4 axis to restrain ferroptosis

Figure 5 Hyperoside improves viability and reduces high glucose-induced apoptosis by inhibiting ferroptosis. ^bP < 0.01, ^dP < 0.001. One-way analysis of variance + Tukey’s post hoc test; two-sided. Data are expressed as the mean ± SD; n = 3 independent experiments. A: Cell Counting Kit-8 time course: Control, high glucose (HG) (30 mmol/L), HG + hyperoside (50 μM), and HG + hyperoside (50 μM) + erastin (5 μM); B: Terminal deoxynucleotidyl transferase dUTP nick-end labeling apoptosis; C: Lipid reactive oxygen species; D: Western blot analysis of Nrf2, SLC7A11, and GPX4 expression. HG: High glucose; OD: Optical density; DAPI: 4’,6-diamidino-2-phenylindole; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick-end labeling; DCF: 2,7’-dichlorofluorescein; FITC-A: Fluorescein isothiocyanate-area.